Evidence map›Paper›PMID 36291935›Full record

ArticleCancers2022

Doped Ferrite Nanoparticles Exhibiting Self-Regulating Temperature as Magnetic Fluid Hyperthermia Antitumoral Agents, with Diagnostic Capability in Magnetic Resonance Imaging and Magnetic Particle Imaging.

Federica Vurro, Marco Gerosa, Alice Busato, Matilde Muccilli, Emil Milan, Jeff Gaudet, Patrick Goodwill, James Mansfield, Enrico Forlin, Alessandro Negri and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Federica VurroDepartment of Computer Science, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Marco GerosaDepartment of Diagnostics and Public Health, University of Verona, Piazzale L.A. Scuro, 37134 Verona, Italy.
Alice BusatoDepartment of Computer Science, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Matilde MuccilliDepartment of Computer Science, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
Emil MilanNanomaterials Research Group, Department of Biotechnology, University of Verona and INSTM, RU Verona, Strada Le Grazie 15, 37134 Verona, Italy.ORCID 0000-0002-5966-0543
Jeff GaudetMagnetic Insight Inc., Alameda, CA 94501, USA.
Patrick GoodwillMagnetic Insight Inc., Alameda, CA 94501, USA.
James MansfieldMagnetic Insight Inc., Alameda, CA 94501, USA.
Enrico ForlinM.B.N. Nanomaterialia S.p.A., Via Giacomo Bortolan, 42, 31050 Carbonera Treviso, Italy.ORCID 0000-0002-4705-5776
Alessandro NegriDepartment of Diagnostics and Public Health, University of Verona, Piazzale L.A. Scuro, 37134 Verona, Italy.ORCID 0000-0002-7828-2947
Filippo GherlinzoniFoundation for Nanotheranostics Research in Cancer Therapy, RNC, 31100 Treviso, Italy.
Giovanni MoranaFoundation for Nanotheranostics Research in Cancer Therapy, RNC, 31100 Treviso, Italy.ORCID 0000-0003-3144-2963
Michele GottardiFoundation for Nanotheranostics Research in Cancer Therapy, RNC, 31100 Treviso, Italy.
Paolo MatteazziM.B.N. Nanomaterialia S.p.A., Via Giacomo Bortolan, 42, 31050 Carbonera Treviso, Italy.
Max WintermarkDepartment of Radiology, Stanford University Hospital, Stanford, CA 94305, USA.
Adolfo SpeghiniNanomaterials Research Group, Department of Biotechnology, University of Verona and INSTM, RU Verona, Strada Le Grazie 15, 37134 Verona, Italy.ORCID 0000-0002-6840-0006
Pasquina MarzolaDepartment of Computer Science, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.ORCID 0000-0001-6936-8901
University of Verona · ITMBN Nanomaterialia (Italy) · ITStanford University · US

Funding

Foundation for Nanotheranostics Research in Cancer Therapy, RNC (Treviso, Italy) Not available
6 · The paper itself

Abstract

This paper reports a comprehensive investigation of a magnetic nanoparticle (MNP), named M55, which belongs to a class of innovative doped ferrite nanomaterials, characterized by a self-limiting temperature. M55 is obtained from M48, an MNP previously described by our group, by implementing an additional purification step in the synthesis. M55, after citrate and glucose coating, is named G-M55. The present study aimed to demonstrate the properties of G-M55 as a diagnostic contrast agent for MRI and magnetic particle imaging (MPI), and as an antitumoral agent in magnetic fluid hyperthermia (MFH). Similar specific absorption rate values were obtained by standard MFH and by an MPI apparatus. This result is of interest in relation to the application of localized MFH by MPI apparatus. We demonstrated the biocompatibility of G-M55 in a triple-negative human breast cancer line (MDA-MB-231), and its efficacy as an MFH agent in the same cell line. We also demonstrated the efficacy of MFH treatment with G-M55 in an experimental model of breast cancer. Overall, our results pave the way for the clinical application of G-M55 as an MFH agent in breast cancer therapy, allowing not only efficient treatment by both standard MFH apparatus and MPI but also temperature monitoring.

Indexed as

breast cancermagnetic fluid hyperthermiaMPIMRIself-regulating temperature

Identifiers

PMID36291935
PMCPMC9600860
OpenAlexW4306921015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.